Analyst Rating Update on Cerus Corporation (CERS)

Cerus Corporation (NASDAQ:CERS) : 4 brokerage houses believe that Cerus Corporation (NASDAQ:CERS) is a Strong Buy at current levels. Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 4 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.

Cerus Corporation (NASDAQ:CERS) : 4 Wall Street analysts covering Cerus Corporation (NASDAQ:CERS) believe that the average level the stock could reach for the short term is $9.25. The maximum price target given is $10 and the minimum target for short term is around $8, hence the standard deviation is calculated at $0.96.

For this week, the average consensus of the company shares are rated as a Strong Buy. Also, Equity Analysts at the BTIG Research maintains the rating on Cerus Corporation (NASDAQ:CERS). The brokerage firm has issued a Buy rating on the shares. The Analysts at the ratings agency raises the price target from $8 per share to $10 per share. The rating by the firm was issued on April 22, 2016.

Cerus Corporation (NASDAQ:CERS): stock turned positive on Tuesday. Though the stock opened at $5.91, the bulls momentum made the stock top out at $6.02 level for the day. The stock recorded a low of $5.9 and closed the trading day at $5.99, in the green by 2.04%. The total traded volume for the day was 1,302,175. The stock had closed at $5.87 in the previous days trading.

In an insider trading activity, The officer (Chief Legal Officer), of Cerus Corp, Menard Chrystal had unloaded 8,541 shares at $5.62 per share in a transaction on March 11, 2016. The total value of transaction was $48,000. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.

Cerus Corporation is a biomedical products company engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Companys INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including HIV, West Nile, SARS, hepatitis B and C; bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company has commercial rights for its INTERCEPT Blood System for three blood components: platelets, plasma and red blood cells. The INTERCEPT Blood System for platelets or platelet system and the INTERCEPT Blood System for plasma or plasma system are being marketed and sold in a number of countries, including the United States, certain countries in Europe, The Commonwealth of Independent States (CIS) and the Middle East. The INTERCEPT Blood System for red blood cells is in development-stage.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.